Etanercept treatment for children and adolescents with plaque psoriasis.

  title={Etanercept treatment for children and adolescents with plaque psoriasis.},
  author={Amy S. Paller and Elaine C Siegfried and Richard G. B. Langley and Alice B. Gottlieb and David M. Pariser and Ian Landells and Adelaide A. Hebert and Lawrence F. Eichenfield and Vaishali G. Patel and Kara Creamer and Angelika Jahreis},
  journal={The New England journal of medicine},
  volume={358 3},
BACKGROUND Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis. METHODS In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body… 

Figures and Tables from this paper

Long-term etanercept in pediatric patients with plaque psoriasis.

Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study

Etanercept was an effective and well-tolerated treatment in this real-life cohort of patients and the medication was overall well tolerated.

Continuous Treatment of Plaque-Type Psoriasis with Etanercept: An Observational Long-Term Experience

The continuous etanercept regimen provided a consistent improvement in both clinical disease parameters and PRO measures, and patients showed statistically significant and meaningful improvements at week 96.

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.

To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival and rate and duration of adherence to a specific drug of methotrexate vs biologics in plaque Psoriasis in children, retrospective medical records review was conducted at 20 European and North American centers.

Etanercept for the treatment of psoriasis

The number of studies of medium- and long-term efficacy and safety is increasing steadily; these studies support the use of etanercept in a maintenance setting, with an apparently more favorable risk: benefit ratio than traditional systemic treatments.

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

The introduction of etanercept and other bDMARDs as therapeutic options for patients with autoimmune rheumatic diseases and spondyloarthropathies revolutionized disease management and these agents continue to have a central role in treatment strategies.

Etanercept in childhood psoriasis: An experience from Kuwait

This work presents the experience of treating eighteen pediatric patients with generalized, recalcitrant stable plaque psoriasis with etanercept therapy, and indicates that this therapy is the closest to achieve the approval for the treatment of moderately severe plaque Psoriasis in children.

Successful Treatment of Severe Psoriasis in an Adolescent with Ustekinumab

The case of a 12‐year‐old boy with severe, refractory, chronic plaque psoriasis for 6 years is described and ustekinumab was initiated and the patient showed a rapid, excellent, sustained response.



Etanercept as monotherapy in patients with psoriasis.

The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks, paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures.

A randomized trial of etanercept as monotherapy for psoriasis.

Etanercept monotherapy provided significant benefit to patients with psoriasis and had a favorable safety profile, and all other measures confirmed the efficacy of etanercept.

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.

Etanercept offers an acceptable safety profile in children with polyarticular-course juvenile rheumatoid arthritis and provides significant improvement in disease manifestations that are sustained for > or = 4 years.

Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.

Etanercept concentrations in subjects with psoriasis are similar to the concentrations inSubjects with rheumatoid arthritis were highly consistent across clinical trials.

Severe psoriasis--oral therapy with a new retinoid.

Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.

Disease concomitance in psoriasis.

Oral retinoid therapy for dermatologic conditions in children and adolescents.

In this learning activity, participants should be familiar with use of oral retinoids for childhood dermatologic conditions such as psoriasis, acne, and ichthyoses as well as safety and risks associated with Oral retinoid use in children and adolescents.

Pediatric psoriasis and psoriatic arthritis

This review attempts to define and consolidate the current state of knowledge with regards to this disease spectrum and the need to investigate treatment options in the pediatric population is discussed.